Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDN-001 in Unresectable Primary Hepatocellular Carcinoma
NCT07391839Phase 1Recruiting
- Sponsor
- Suzhou Mednovo Yi Medical Technology
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MDN-001 in hepatocellular carcinoma (HCC), sponsored by Suzhou Mednovo Yi Medical Technology. Primary endpoints: Adverse Events at 12 months, Objective Remission Rate at 6 months and 9 more. Started Aug 2025; status: recruiting.
02
Drugs
MDN-001
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07391839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07391839.